Asia has become one of the world’s fastest-growing biopharma markets, with revenues projected to surpass USD133 billion by 2033. From AI-enabled drug discovery and biologics to advanced manufacturing and clinical research, the region is rapidly emerging as the global centre of pharmaceutical innovation.
In this video, Asian Insiders Managing Partner, Jari Hietala, explores why Asia is now shaping the future of biopharma. Discover how China, India, South Korea, Singapore, Japan and Southeast Asia are driving the next wave of innovation through increased R&D investment, government support, expanding clinical trials and world-class manufacturing capabilities.
Learn where the biggest opportunities exist for international companies across the biopharma value chain, from research and development to manufacturing, licensing and strategic partnerships. The video also examines the challenges businesses must navigate, including intellectual property protection, regulatory differences and market-specific requirements.
As global investment and innovation continue shifting towards Asia, understanding the region’s diverse biopharma ecosystem has never been more important for companies looking to compete in the future of healthcare.
Subscribe to Asian Insiders for expert insights into Asia’s biggest opportunities!
